Cargando…
Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans
CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099165/ https://www.ncbi.nlm.nih.gov/pubmed/36459457 http://dx.doi.org/10.1210/clinem/dgac699 |
_version_ | 1785024992771047424 |
---|---|
author | Sommer, Christine Vangberg, Kjersti G Moen, Gunn-Helen Evans, David M Lee-Ødegård, Sindre Blom-Høgestøl, Ingvild K Sletner, Line Jenum, Anne K Drevon, Christian A Gulseth, Hanne L Birkeland, Kåre I |
author_facet | Sommer, Christine Vangberg, Kjersti G Moen, Gunn-Helen Evans, David M Lee-Ødegård, Sindre Blom-Høgestøl, Ingvild K Sletner, Line Jenum, Anne K Drevon, Christian A Gulseth, Hanne L Birkeland, Kåre I |
author_sort | Sommer, Christine |
collection | PubMed |
description | CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI), food intake, and physical activity. METHODS: We performed an epidemiological triangulation combining cross-sectional, interventional, and Mendelian randomization study designs. In 5 independent clinical studies (n = 24-823), sOb-R was quantified in serum or plasma by commercial enzyme-linked immunosorbent assay kits using monoclonal antibodies. We performed mixed-model regression and 2-sample Mendelian randomization. RESULTS: In pooled, cross-sectional data, leveling by study, sOb-R was associated inversely with BMI (β [95% CI] −0.19 [−0.21 to −0.17]), body fat (−0.12 [−0.14 to −0.10), and fasting C-peptide (−2.04 [−2.46 to −1.62]). sOb-R decreased in response to acute hyperinsulinemia during euglycemic glucose clamp in 2 independent clinical studies (−0.5 [−0.7 to −0.4] and −0.5 [−0.6 to −0.3]), and immediately increased in response to intensive exercise (0.18 [0.04 to 0.31]) and food intake (0.20 [0.06 to 0.34]). In 2-sample Mendelian randomization, higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (inverse variance weighted, −1.72 [−2.86 to −0.58], and −0.20 [−0.36 to −0.04], respectively). The relationship between hyperglycemia and sOb-R was inconsistent in cross-sectional studies and nonsignificant in intervention studies, and 2-sample Mendelian randomization suggested no causal effect of fasting glucose on sOb-R. CONCLUSION: BMI and insulin both causally decreased serum sOb-R levels. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results suggest that sOb-R is involved in short-term regulation of leptin signaling, either directly or indirectly, and that hyperinsulinemia may reduce leptin signaling. |
format | Online Article Text |
id | pubmed-10099165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100991652023-04-14 Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans Sommer, Christine Vangberg, Kjersti G Moen, Gunn-Helen Evans, David M Lee-Ødegård, Sindre Blom-Høgestøl, Ingvild K Sletner, Line Jenum, Anne K Drevon, Christian A Gulseth, Hanne L Birkeland, Kåre I J Clin Endocrinol Metab Clinical Research Article CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI), food intake, and physical activity. METHODS: We performed an epidemiological triangulation combining cross-sectional, interventional, and Mendelian randomization study designs. In 5 independent clinical studies (n = 24-823), sOb-R was quantified in serum or plasma by commercial enzyme-linked immunosorbent assay kits using monoclonal antibodies. We performed mixed-model regression and 2-sample Mendelian randomization. RESULTS: In pooled, cross-sectional data, leveling by study, sOb-R was associated inversely with BMI (β [95% CI] −0.19 [−0.21 to −0.17]), body fat (−0.12 [−0.14 to −0.10), and fasting C-peptide (−2.04 [−2.46 to −1.62]). sOb-R decreased in response to acute hyperinsulinemia during euglycemic glucose clamp in 2 independent clinical studies (−0.5 [−0.7 to −0.4] and −0.5 [−0.6 to −0.3]), and immediately increased in response to intensive exercise (0.18 [0.04 to 0.31]) and food intake (0.20 [0.06 to 0.34]). In 2-sample Mendelian randomization, higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (inverse variance weighted, −1.72 [−2.86 to −0.58], and −0.20 [−0.36 to −0.04], respectively). The relationship between hyperglycemia and sOb-R was inconsistent in cross-sectional studies and nonsignificant in intervention studies, and 2-sample Mendelian randomization suggested no causal effect of fasting glucose on sOb-R. CONCLUSION: BMI and insulin both causally decreased serum sOb-R levels. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results suggest that sOb-R is involved in short-term regulation of leptin signaling, either directly or indirectly, and that hyperinsulinemia may reduce leptin signaling. Oxford University Press 2022-12-02 /pmc/articles/PMC10099165/ /pubmed/36459457 http://dx.doi.org/10.1210/clinem/dgac699 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Article Sommer, Christine Vangberg, Kjersti G Moen, Gunn-Helen Evans, David M Lee-Ødegård, Sindre Blom-Høgestøl, Ingvild K Sletner, Line Jenum, Anne K Drevon, Christian A Gulseth, Hanne L Birkeland, Kåre I Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title | Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title_full | Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title_fullStr | Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title_full_unstemmed | Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title_short | Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans |
title_sort | insulin and body mass index decrease serum soluble leptin receptor levels in humans |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099165/ https://www.ncbi.nlm.nih.gov/pubmed/36459457 http://dx.doi.org/10.1210/clinem/dgac699 |
work_keys_str_mv | AT sommerchristine insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT vangbergkjerstig insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT moengunnhelen insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT evansdavidm insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT leeødegardsindre insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT blomhøgestølingvildk insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT sletnerline insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT jenumannek insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT drevonchristiana insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT gulsethhannel insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans AT birkelandkarei insulinandbodymassindexdecreaseserumsolubleleptinreceptorlevelsinhumans |